Pressure Builds on the U.S. to Facilitate Biogenerics

Almost 50 pro-patient groups in the U.S. representing tens of millions of Americans are pressing the U.S. government to introduce legislation that would facilitate the sale of biologic generic drugs—known as biogenerics or biosimilars, according to the generic pharmaceuticals industry trade group Generic Pharmaceutical Association (GPhA; Arlington, VA). Currently, the U.S. does not have a formal body of legislation to facilitate the market approval of biogenerics. Jaeger: Competition is needed. Congress debated new legislation last week that would enable...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers